Bevacizumab, which targets VEGF, was approved by the Food and Drug Administration in 2006 for treating advanced NSCLC,89 and several VEGFR tyrosine kinase inhibitors have been approved in combination with chemotherapy for metastatic NSCLC.90 The gene discussed is KDR; the disease is non-small cell lung carcinoma.